A protein that contributes to the rejection of transplanted hearts has been identified by a UCSF research team. The finding raises hopes for future developments that may boost transplant success and reduce the side effects of current anti-rejection drugs.
In his 41 years as a professor and electrophysiologist at UCSF, Melvin Scheinman, MD, has shocked thousands of hearts back to health with a procedure called ablation therapy.
"The injected cells survive and slow down abnormal heart rhythms," says Jeffrey Olgin, MD, the physician and researcher who heads the Cardiac Electrophysiology and Arrhythmia Service at UCSF.
Words like "pioneering," "original," and "premier," can sometimes overstate a single person's contributions to any field, let alone a medical research specialty, which often moves along lines of collaboration and consensus.
A discussion about the health and human rights among women in Afghanistan today, sponsored by the UCSF National Center of Excellence in Women's Health.